BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20626385)

  • 1. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells.
    Sewgobind VD; Quaedackers ME; van der Laan LJ; Kraaijeveld R; Korevaar SS; Chan G; Weimar W; Baan CC
    Am J Transplant; 2010 Aug; 10(8):1785-95. PubMed ID: 20626385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells.
    Passerini L; Allan SE; Battaglia M; Di Nunzio S; Alstad AN; Levings MK; Roncarolo MG; Bacchetta R
    Int Immunol; 2008 Mar; 20(3):421-31. PubMed ID: 18270368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
    Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
    Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL‑2 and TGF‑β by CD4+ T cells via the STAT5 signaling pathway.
    Wang R; Huang K
    Mol Med Rep; 2020 Jun; 21(6):2522-2532. PubMed ID: 32323817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.
    Singh M; Basu S; Camell C; Couturier J; Nudelman RJ; Medina MA; Rodgers JR; Lewis DE
    Eur J Immunol; 2008 Jun; 38(6):1522-32. PubMed ID: 18446791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naïve CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro.
    Singh AK; Horvath KA; Mohiuddin MM
    Transplant Proc; 2009; 41(1):418-21. PubMed ID: 19249569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3- cells versus regulatory T cells: a whole blood perspective.
    Dupont G; Demaret J; Venet F; Malergue F; Malcus C; Poitevin-Later F; Morel J; Monneret G
    Cytokine; 2014 Sep; 69(1):146-9. PubMed ID: 24947990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proliferation of CD4+ CD25+ regulatory T cells of rat by different cytokines in vitro].
    Wang ZH; Zhu JY; Li T; Leng XS
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):844-7. PubMed ID: 18756991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.
    Cabrera R; Ararat M; Eksioglu EA; Cao M; Xu Y; Wasserfall C; Atkinson MA; Liu C; Nelson DR
    Scand J Immunol; 2010 Oct; 72(4):293-301. PubMed ID: 20883314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.
    Goldberg R; Clough JN; Roberts LB; Sanchez J; Kordasti S; Petrov N; Hertweck A; Lorenc A; Jackson I; Tasker S; Appios A; Omer O; Parkes M; Prescott N; Jenner RG; Irving PM; Lord GM
    J Crohns Colitis; 2021 Dec; 15(12):2054-2065. PubMed ID: 34120187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
    Cabrera R; Ararat M; Xu Y; Brusko T; Wasserfall C; Atkinson MA; Chang LJ; Liu C; Nelson DR
    Cancer Immunol Immunother; 2013 Apr; 62(4):737-46. PubMed ID: 23223899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
    Wang Z; Xiao L; Shi BY; Qian YY; Bai HW; Chang JY; Cai M
    Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.
    Bloom DD; Chang Z; Fechner JH; Dar W; Polster SP; Pascual J; Turka LA; Knechtle SJ
    Am J Transplant; 2008 Apr; 8(4):793-802. PubMed ID: 18261176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.
    Strauss L; Czystowska M; Szajnik M; Mandapathil M; Whiteside TL
    PLoS One; 2009 Jun; 4(6):e5994. PubMed ID: 19543393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD26: a negative selection marker for human Treg cells.
    Salgado FJ; Pérez-Díaz A; Villanueva NM; Lamas O; Arias P; Nogueira M
    Cytometry A; 2012 Oct; 81(10):843-55. PubMed ID: 22949266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
    Xia G; He J; Zhang Z; Leventhal JR
    Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of CD4+ CD25bright T cells in kidney transplant patients: improving suppression of donor-directed responses after transplantation.
    Sewgobind VD; van der Laan LJ; Klepper M; Ijzermans JN; Tilanus HW; Weimar W; Baan CC
    Clin Transplant; 2008; 22(5):579-86. PubMed ID: 18435785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the frequencies and functions of CD4
    Zare M; Namavar Jahromi B; Gharesi-Fard B
    J Reprod Immunol; 2019 Jun; 133():43-51. PubMed ID: 31255887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
    Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
    Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.